Keywords 2 1 linezolid; rifampicin; pharmacokinetics; metabolic enzymes 2 2 2 3 Word count: 1,658 words 2 4 Abstract 2 6
Linezolid concentrations were measured using an HPLC method with ultraviolet 1 0 2 (UV) detection, according to a previously reported method [12] . Dexamethasone 1 0 3 concentrations were measured using an HPLC method with UV detection. The HPLC system Separation was performed on an ODS Hypersil column (Cadenza 5CD-C18, 150 mm × 4.6 1 0 7 mm, 5 µm; Imtakt Co.). A solution of 1% phosphoric acid was used for the mobile phase, and 1 0 8 pH was adjusted to 5 by the addition of 10 M sodium hydroxide. The pump flow rate was 1.0 1 0 9 mL/min. The column temperature was maintained at 40°C. The wavelength of optimum UV 1 1 0 detection was set at 254 nm. Calibration curves were linear over a concentration range of 1 to 1 1 1 100 µg/mL. Intra/inter-day CV was less than 5.0%, and LLOQ was 1 μ g/mL for 1 1 2 dexamethasone concentrations. An unpaired t-test was used to analyze differences between two groups. Dunnett's 1 1 5 test was used for post-hoc comparisons. Differences between the groups with a P value of < 1 1 6 0.05 were considered to be significant. In order to investigate whether a rifampicin pre-treatment influences the absorption, 1 2 0 metabolism, and elimination of linezolid, mice were orally administered linezolid one day 1 2 1 after the rifampicin pre-treatment and blood linezolid concentrations were measured using 1 2 2 HPLC. The rifampicin pre-treatment reduced linezolid blood concentrations at all sampling 1 2 3 points, and decreased AUC by 30% from that in the control group ( Figure 1A) . In order to 1 2 4 clarify whether the rifampicin pre-treatment promotes the metabolic or eliminated process, 1 2 5 linezolid was intravenously administered one day after an injection of rifampicin and linezolid 1 2 6 blood concentrations were then measured using HPLC. The results obtained showed that 1 2 7 linezolid blood concentrations were reduced by the rifampicin pre-treatment ( Figure 1B ). Rifampicin induces the expression of CYP3A4, and mouse Cyp3a11 is homologous 1 3 1 with human CYP3A4 [13] [14] [15] . We investigated the induction of Cyp3a11 expression by the 1 3 2 rifampicin pre-treatment, and found that Cyp3a11 levels were higher than those in the control reduced by the extract solution by liver pre-treated with rifampicin. Since dexamethasone is 1 3 8 metabolized by CYPs, we performed the same experiment using dexamethasone as a positive 1 3 9 control. Dexamethasone concentrations were reduced by the extract solution by liver 1 4 0 pre-treated with rifampicin ( Figure 2B ). Linezolid uses a novel mechanism of action against microbes, and its antibiotic 1 4 3 effects are induced when it is combined with other antibiotics. Since linezolid is not and this has recently been attracting increasing attention [9, 17] . In the present study, in order to avoid direct interactions with rifampicin, mice were 1 4 8 treated with rifampicin once per day for 7 days until one day before the administration of 1 4 9 linezolid. Linezolid blood concentrations were reduced by the rifampicin pre-treatment. To 1 5 0 the best of our knowledge, rifampicin is a substrate of some organic anion transporting 1 5 1 polypeptides (OATPs), but does not induce the expression of these transporters. P-gp is an 1 5 2 efflux transporter, and its inhibition has been shown to increase AUC, thereby reducing drug 1 5 3 elimination [18] . Previous studies reported that rifampicin is a pregnane X receptor (PXR) 1 5 4 ligand that induces P-gp [19, 20] . Rifampicin affects the concentrations of other drugs through 1 5 5 P-gp [21] . However, linezolid is not a substrate of P-gp or OATP according to Pfizer, and a 1 5 6 previous study also suggested that these transporters do not affect its pharmacokinetics [9] . Therefore, the present results indicated that efflux transporters did not affect the 1 5 8 pharmacokinetics of linezolid after the rifampicin pre-treatment. Rifampicin also induces CYP3A expression via PXR [22] . Dexamethasone is a 1 6 0 1 2 substrate of CYPs, and its concentration decreased in the in vitro experiments conducted in 1 6 1 the present study, whereas that of linezolid did not. Previous studies suggested that linezolid is 1 6 2 not a substrate of or is poorly metabolized by CYPs [2, 16] . Moreover, the total protein 1 6 3 solution, extracted from liver after rifampicin or dexamethasone treatment, were used in in 1 6 4 vitro study. Therefore, these findings suggest that the pharmacokinetics of linezolid are Undesired reductions in blood antibiotic concentrations lead to failed drug treatments 1 6 7 and the emergence of antibiotic-resistant bacteria. We herein demonstrated that linezolid 1 6 8 blood concentrations were reduced by the rifampicin pre-treatment, which affected drug 1 6 9 absorption and metabolism/elimination. Liver metabolic enzymes did not affect the 1 7 0 pharmacokinetics of linezolid with the rifampicin pre-treatment. Previous studies suggested 1 7 1 that linezolid is metabolite by the lactone and lactam pathway [23, 24] . Although it is unclear 1 7 2 that rifampicin induces the lactone and lactam pathway, these results suggest that transporters 1 7 3 and liver metabolic enzymes poorly affect the pharmacokinetics of linezolid in rifampicin 1 7 4 combination therapy. Approval was not required. The authors declare no conflict of interest associated with this manuscript. PubMed PMID: 24973908. 
